H.C. Wainwright lowered the firm’s price target on AnaptysBio (ANAB) to $52 from $59 and keeps a Buy rating on the shares after the Phase 2 rosnilimab trial in ulcerative colitis does not meet the primary endpoint. The firm removed ulcerative colitis revenues from its model.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB: